Anthropic, one of the world’s leading artificial intelligence companies, has called for a slowdown in the development of advanced AI systems, warning that humanity may be approaching a point where the technology becomes difficult to control.

The company behind the Claude chatbot said it would support a temporary pause in developing more powerful AI models if other leading developers agreed to do the same.

Anthropic argued that a slowdown could provide governments, researchers, and society with more time to understand and manage the risks associated with increasingly capable AI systems.

The warning comes as Anthropic continues to position itself as one of the industry’s strongest advocates for AI safety. The company has reportedly withheld public access to its most advanced AI system, known as Mythos, because of concerns that it could be misused for large-scale cyberattacks and other harmful activities.

Researchers warn of self-improving AI

In an essay published Thursday, Marina Favaro, head of Anthropic’s research division, and company president Jack Clark said AI may be approaching a critical milestone known as “recursive self-improvement.”

The concept refers to AI systems helping design and improve future generations of AI with decreasing human involvement. Researchers said such a development could rapidly accelerate technological progress but also introduce new challenges for oversight and control.

LATEST: Claude maker Anthropic is calling for a global pause in AI development, warning that models are approaching the ability to self-improve without human intervention. pic.twitter.com/7WM9jmDZjt

— Cointelegraph (@Cointelegraph) June 4, 2026

Favaro and Clark pointed to growing evidence that AI is already contributing to its own development. According to the company, employees now produce roughly eight times more code than they did between 2021 and 2025, largely because of AI-assisted software development. The researchers also said AI systems are becoming better at generating ideas, planning research, and supporting scientific work.

Anthropic Chief Executive Officer Dario Amodei has previously warned about the potential risks of advanced AI, estimating there is a 25% chance that the technology could lead to severe negative outcomes if it is not developed responsibly.

A global pause would be difficult

Despite advocating caution, Anthropic acknowledged that coordinating a worldwide slowdown would be extremely challenging.

The company said any meaningful pause would require cooperation among leading AI laboratories across multiple countries. It also noted that verifying compliance would be difficult because AI training runs can be conducted privately and are far less visible than traditional military infrastructure.

Anthropic compared the competition to develop advanced AI to an arms race, arguing that companies may feel pressure to move faster to avoid falling behind rivals.

Critics question the warnings

Not all experts agree with Anthropic’s assessment. Some researchers and industry observers argue that AI companies may be overstating the capabilities of current systems or emphasizing risks to encourage regulations that could disadvantage competitors.

The debate comes amid growing uncertainty in the AI sector. Shares of semiconductor company Broadcom recently fell sharply after disappointing investors with its sales outlook, triggering a broader decline among AI-related chipmakers and renewing concerns that enthusiasm surrounding artificial intelligence may have outpaced market realities.

As AI capabilities continue to advance, questions about safety, governance, and oversight are expected to remain central to the global conversation surrounding the technology.

A farmacêutica EMS anunciou os preços da Ozivy, primeira caneta de semaglutida produzida no Brasil. O medicamento chegará ao mercado com valores a partir de R$ 452, abaixo dos praticados atualmente por concorrentes importados que utilizam o mesmo princípio ativo.

A semaglutida é a substância utilizada em medicamentos como Ozempic e Wegovy, indicados para o tratamento do diabetes tipo 2 e da obesidade. A entrada da versão nacional ocorre após o fim da patente da molécula no Brasil, abrindo espaço para novos fabricantes no mercado.

Segundo a EMS, a estratégia é oferecer o produto por valores cerca de 30% inferiores aos dos medicamentos concorrentes. A empresa estima comercializar mais de 1 milhão de unidades no primeiro ano e projeta faturamento de aproximadamente R$ 500 milhões com o novo medicamento.

Antes do anúncio dos preços ao consumidor, a Câmara de Regulação do Mercado de Medicamentos (CMED) já havia definido o teto regulatório da Ozivy. O limite aprovado ficou no mesmo patamar dos medicamentos de referência à base de semaglutida, como Ozempic e Wegovy.

A chegada da Ozivy é vista pelo setor como um marco para a indústria farmacêutica nacional, já que se trata da primeira caneta de semaglutida desenvolvida e produzida por uma empresa brasileira. Especialistas avaliam que o aumento da concorrência pode contribuir para ampliar o acesso ao tratamento e pressionar os preços para baixo nos próximos meses.

The post ”Ozempic” 100% brasileiro custará R$452,00 appeared first on Diário da Manhã - O Jornal do leitor Inteligente.

Opal, the company famous for making a fancy webcam, has pivoted to making other consumer electronics. Fueled by big investments from OpenAI and Samsung, it’s working on an audio gadget first.

CONCEPCIÓN DE SOLUTECA, Honduras — In the 1970s, the Honduran government granted a piece of land in the mountains of Concepción de Soluteca to Roberto González’s parents. They duly grabbed a chainsaw and a machete to clear the forest. On the 12 hectares (30 acres) they received as part of a land reform, they planted corn, beans and bananas, the basic staple foods. It was a hard life up in the mountains, allowing the farmers and their families to just survive. There wasn’t much public infrastructure, and most children had to help with farmwork early on. This included González, who only attended elementary school for three years. When González inherited the land 20 years later, coffee cultivation was just taking off. Middlemen promised the farmers good money for the export crop, and the banks provided loans for cultivation. At first, this worked well, González, now 39, remembers. Coffee helped the farmers to generate income and improve living conditions. But it didn’t last long. They grew coffee much the same way they did other crops, without adequate soil or shade management. When harvests dwindled, they expanded their area, cutting the last standing forests and damaging water sources. Around 2012, they faced an outbreak of coffee rust, a fungal disease. It was a complete disaster: many farmers were thrown into poverty and forced to migrate. “We destroyed the foundations of our livelihoods, but it was out of ignorance; we just didn’t know better,” González tells Mongabay. Under the EUDR, coffee farmers step…This article was originally published on Mongabay